What the science says about vaginal lubricants

Science library Health and safety

Last reviewed: Written and reviewed by the Loviux Team. 5 studies

We check every summary against the study's original abstract: the quotation is verbatim and the figures match. How we verify our information

This page reports on published research. It is not medical advice and does not replace a healthcare professional.

If you have pain or discomfort, speak to a healthcare professional.

On this page
  1. In 30 seconds
  2. What the studies say overall
  3. Where they disagree
  4. Limits of the evidence
  5. The studies, one by one
  6. What this means in practice
  7. Other topics in the library

In 30 seconds

What the studies say
Almost all clinical research on lubricants has been done with postmenopausal women or women treated for cancer, with vaginal dryness and pain during intercourse.
The main limitation
The trials are small and have been carried out with very specific populations (postmenopausal women, people with cancer) and over a few weeks.
In practice
The evidence comes from clinical settings, with follow-up by healthcare professionals. If dryness or pain are frequent or persist, it is reasonable to speak to a professional about it.

What kind of studies there are

  • Syntheses of studies 1
  • Randomised trials 2
  • Observational 1
  • Descriptive or expert opinion 1

We classify each study by its design. A synthesis of many studies or a randomised trial supports firmer conclusions than a survey or an expert opinion. The design does not tell you whether a result is good or bad.

What the studies say overall

Almost all clinical research on lubricants has been done with postmenopausal women or women treated for cancer, with vaginal dryness and pain during intercourse.

In this group, a network meta-analysis of trials found that vaginal lubricant was more effective than a sham treatment at reducing sexual dysfunction measured with the FSFI questionnaire, although its effect was smaller than that of oestrogens and laser in the same analysis.

A randomised trial with postmenopausal women with pain during intercourse found that lubricant gel used before intercourse improved sexual function and pain to a degree comparable to a vaginal oestrogen.

For women with breast cancer being treated with tamoxifen, a small trial observed an improvement in sexual function after using lubricant for 30 days.

And a comparison of four clinical guidelines for cancer survivors indicates that all of them recommend non-hormonal lubricants or moisturisers as the first option for vaginal dryness.

Where they disagree

An analysis of the placebo groups of two trials found no differences in cell maturity or vaginal pH between those who used lubricant and those who did not. In other words, lubricants have been studied for their effect on comfort during intercourse, not for changing the tissue.

Limits of the evidence

The trials are small and have been carried out with very specific populations (postmenopausal women, people with cancer) and over a few weeks. The meta-analysis compares treatments indirectly.

The results cannot simply be extrapolated to young women without symptoms, and the studies do not compare brands or types of lubricant.

The studies, one by one

We have gathered 5 verified studies. Each summary is our own; the quotation in inverted commas is taken word for word from the original abstract, in English.

In this guide (7)
Type of study: Meta-analysis2024

Physical energies for the management of genitourinary syndrome of menopause: An overview of a systematic review and network meta-analysis.

What they found: Vaginal lubricant was more effective than sham treatment at reducing sexual dysfunction, with a resulting increase in the Female Sexual Function Index (FSFI) score. (Sarmento et al., 2024)

Population Postmenopausal women with symptoms of genitourinary syndrome of menopause Journal Int J Gynaecol Obstet

Verbatim quotation from the original abstract (in English)

“vaginal lubricant (SMD 1.37, 95% CI 0.54-2.20) were more effective than sham for reducing sexual dysfunction, with a consequent increase in Female Sexual Function Index (FSFI).” Sarmento et al., 2024

See the original: DOI · PubMed

Type of study: Randomised controlled trialSample n = 1162025

The use of vaginal estriol and its effects on sexual intercourse and serum estriol levels in postmenopausal women.

What they found: In a randomised trial with 116 postmenopausal women with pain during intercourse, the group that used lubricant gel before intercourse improved their sexual function (except orgasm) and pain to a degree comparable to vaginal estriol. (de Paula et al., 2025)

Population 116 sexually active postmenopausal women with dyspareunia Journal Menopause

Verbatim quotation from the original abstract (in English)

“Lubricant use also enhanced sexual function (except orgasm) and reduced pain comparably to estriol.” de Paula et al., 2025

See the original: DOI · PubMed

Type of study: Randomised controlled trialSample n = 522017

Can polyacrylic acid treat sexual dysfunction in women with breast cancer receiving tamoxifen?

What they found: In a trial with 52 women with breast cancer being treated with tamoxifen and vaginal dryness, those who used a lubricant for 30 days went from 88.9% to 55.6% with sexual dysfunction (the polyacrylic acid group improved more). (Juliato et al., 2017)

Population 52 women with breast cancer being treated with tamoxifen and vaginal dryness Journal Climacteric

Verbatim quotation from the original abstract (in English)

“There was improvement in the FSFI after both treatments.” Juliato et al., 2017

See the original: DOI · PubMed

Type of study: Analysis of placebo groups from clinical trials2014

Assessment of ospemifene or lubricants on clinical signs of VVA.

What they found: In an analysis of the placebo groups of trials with postmenopausal women with vulvovaginal atrophy, those who used lubricants showed no differences in vaginal physiological effects (cell maturity and pH) compared with those who did not. (Constantine et al., 2014)

Population Postmenopausal women with vulvovaginal atrophy (placebo groups from clinical trials) Journal J Sex Med

Verbatim quotation from the original abstract (in English)

“There was no significant difference in physiologic effects between placebo lubricant users vs. nonusers in either 12-week study.” Constantine et al., 2014

See the original: DOI · PubMed

Type of study: Narrative review2025

2024 SOGC, 2024 NCCN, 2022 ESO-ESMO, and 2018 ASCO: a comparison of female cancer survivorship guidelines for the management of sexual health concerns.

What they found: A comparison of four clinical guidelines for cancer survivors indicates that all of them recommend non-hormonal lubricants or moisturisers as the first option for vaginal dryness. (Bhinder et al., 2025)

Population Women who are cancer survivors (comparative review of clinical guidelines) Journal Support Care Cancer

Verbatim quotation from the original abstract (in English)

“All guidelines strongly recommend non-hormonal therapies (i.e., lubricants or moisturizers) as first-line treatments for managing vaginal dryness.” Bhinder et al., 2025

See the original: DOI · PubMed

What this means in practice

  • The evidence comes from clinical settings, with follow-up by healthcare professionals. If dryness or pain are frequent or persist, it is reasonable to speak to a professional about it.
  • The studies do not allow us to say which type or brand of lubricant is better: they do not compare them with each other.

If you have pain or discomfort, speak to a healthcare professional.

Other topics in the library

All topics in the science library